Dual roles of complement in ulcerative colitis: insights from clinical studies and animal research Authors: Zeyi Qin, Ruoxiang Wang, Yi Zhang Published: 2025 ABSTRACT Ulcerative colitis (UC), a major form of inflammatory bowel disease (IBD), is marked by chronic mucosal inflammation and epithelial barrier disruption. The complement system, a central component of the immune system, is a key modulator of UC pathogenesis. Recent studies from clinical observations and dextran sulfate sodium (DSS)-induced murine colitis models reveal that complement activation plays a context-dependent role in UC. Complement components such as C3a, C5a, and the membrane attack complex (MAC) exacerbate mucosal inflammation and epithelial injury by promoting neutrophil recruitment and cytokine storms, while initiator molecules C1q and mannose-binding lectin (MBL) support protective functions, including immune regulation, apoptotic cell clearance, and tissue repair. This review synthesizes current clinical and experimental evidence on the bidirectional roles of the complement system in UC, with emphasis on the regulatory balance between protective and pathogenic pathways. Emerging therapeutics, ranging from C5aR antagonists to colon-targeted complement inhibitors, highlight the translational potential of modulating complement activity in UC. Understanding these mechanisms provides a framework for developing complement-targeted therapies and precision treatment strategies in IBD. Introduction Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis (UC) [1], represents a spectrum of chronic and relapsing autoimmune disorders affecting the gastrointestinal tract [2–4]. UC, the most prevalent subtype, is defined by recurrent or continuous inflammation of the colonic mucosa, typically originating in the rectum and extending proximally [5, 6]. Its pathogenesis is attributed to multifaceted risk factors, including genetic susceptibility, immune dysfunction, dysbiosis of the gut microbiota, and issues of dietary changes, antibiotic use, or urbanization [7–10]. The incidence of IBD has increased dramatically in newly industrialized and emerging regions in Africa, Asia and Latin America, with the prevalence in early industrialized regions continued to grow steadily [11–13]. The prevalence of IBD in the United States is estimated between 2.4 and 3.1 million, with differing burden across age groups [14]. Similar trends are seen in Sub-Saharan Africa and Latin America, driven by shifting environmental and lifestyle factors [11, 13]. The histopathology of UC is characterized by superficial, continuous mucosal inflammation, with common features, including crypt distortion, goblet cell depletion, and epithelial barrier dysfunction [7, 8]. The loss of the mucus layer, largely due to goblet cell depletion and altered mucin secretion, further compromises this barrier, exposing the epithelium to direct contact with luminal microbes and antigens. This facilitates bacterial adherence and penetration into the mucosa, thereby triggering and amplifying innate and adaptive immune responses that sustain inflammation (Fig. 1) [15, 16]. Among the key components of innate immunity, the complement system has garnered increasing attention as a pivotal, yet dual-functional, mediator. Beyond its classical role in opsonization and pathogen lysis, complement activation influences immune cell trafficking, cytokine secretion, and tissue repair. Dysregulated complement activation has been implicated in driving mucosal damage and chronic inflammation in UC and other autoimmune diseases.Fig. 1Schematic illustration of immune balance and breakdown in UC Schematic illustration of immune balance and breakdown in UC Early investigations with clinical specimens have established a strong link between complement activation and UC development [17–22]. Moreover, studies employing dextran sulfate sodium (DSS) in murine models have revealed the diverse roles of complement components in the pathophysiology of IBD. While effector molecules such as C3a, C5a, and the membrane attack complex (MAC) intensify intestinal inflammation, complement initiators, including C1q and mannose-binding lectin (MBL), have been implicated in facilitating epithelial healing and immune tolerance [23–25]. This review aims to integrate current clinical observations from UC patients with mechanistic data derived from DSS-induced colitis models, thereby delineating the context-dependent roles of complement. We further discuss the therapeutic implications of selectively modulating complement activity in IBD management. Complement system: activation pathways and regulatory mechanisms Activation pathways of the complement cascade The complement system, a crucial component of innate immunity, consists of over 30 plasma proteins and membrane-bound regulators [26]. The system can be activated via three distinct pathways, the classical, lectin, and alternative pathways, all of which converge to generate a common set of effector molecules (Fig. 2) [27, 28]. The activation involves sequential proteolytic cleavage events mediated by serine proteases.Fig. 2Schematic illustration of complement activation and regulation Schematic illustration of complement activation and regulation The classical pathway is typically initiated by the binding of the C1 complex (comprising C1q, C1r, and C1s) to immune complexes (IgG or IgM) or to certain surface-associated molecules, such as C-reactive protein or other pentraxins. C1q binding induces conformational changes that activate C1r and C1s, leading to the cleavage of C4 into C4a and C4b, and C2 into C2a and C2b. These fragments assemble to form the classical C3 convertase (C4bC2b) [28, 29]. Efficient C1 activation requires multiple IgG molecules, meaning that both the spatial arrangement of epitopes and the local IgG density within immune complexes critically influence complement activation [30]. The ability to bind complement also varies by IgG subclass. Notably, IgG4 does not activate complement via the classical pathway and may even competitively inhibit C1q binding to IgG1 [31]. The lectin pathway resembles the classical pathway but is activated by pattern recognition molecules, such as mannose-binding lectin (MBL) or ficolins, which bind specific carbohydrate motifs on microbial surfaces. MBL-associated serine proteases (MASP-1 and MASP-2) then cleave C4 and C2 to form the same C3 convertase, C4bC2b [28, 29]. Different from the classical and lectin pathways, the alternative activation pathway is activated spontaneously through the “tick-over” mechanism [32]. Specifically, C3 is hydrolyzed at a low basal rate to yield C3 (H2O), which associates with factor B. This complex is then cleaved by the serine protease factor D, resulting in the formation of the C3 convertase C3bBb. Stabilization of C3bBb by properdin facilitates robust amplification of the complement cascade on microbial surface [33, 34]. All three pathways converge at C3 cleavage, producing C3a, an inflammatory mediator, and C3b, an opsonin essential for phagocytosis. C3b also participates in forming C5 convertases (C4bC2bC3b or C3bBbC3b), which cleave C5 into C5a (a potent anaphylatoxin) and C5b, initiating assembly of the membrane attack complex (MAC) (C5b–C9), which is the cytolytic effector forming pores in the membrane of affected cell [28, 35]. Mechanisms of complement regulation The complement system is a tightly regulated to prevent excessive inflammation and collateral damage to host tissues [32]. Localized, dynamic control of enzymatic activity and complex stability at sites of activation ensure that complement is engaged only where needed and promptly shut down on healthy host cells. The regulation operates at multiple stages across all three activation pathways, mainly via soluble complement regulatory proteins (CRPs) and membrane-bound CRPs that co-exist with complement components (Fig. 2). Soluble CRPs act in plasma and interstitial fluids to intercept complement activation in real time. C1 inhibitor, C1-INH, binds to and inactivates the serine proteases C1r and C1s in the classical pathway, and MASP-1 and MASP-2 in the lectin pathway, thereby halting cleavage of C4 and C2 and preventing formation of the C3 convertase [36, 37]. Factor H (fH) selectively binds C3b deposited on host surfaces and recruits Factor I (fI) to proteolytically cleave C3b into inactive form, thereby disrupting alternative pathway amplification and preventing stable assembly of the C3 convertase (C3bBb) [38]. At the terminal stage, vitronectin (S-protein) and clusterin bind to soluble C5b-7 or C5b-8 complexes, preventing their insertion into membranes and blocking C9 polymerization, thereby inhibiting MAC formations [39, 40]. Membrane-bound CRPs provide cell-surface protection, where activation complexes have already formed. Decay-accelerating factor (DAF/CD55) accelerates dissociation of C3 and C5 convertases by displacing C2a (classical/lectin) or Bb (alternative) subunits, preventing downstream activation of the complement cascade. Moreover, membrane cofactor protein (MCP/CD46) acts as a cofactor for fI-mediated cleavage of C3b and C4b on host cell surfaces, thereby inactivating C3b and C4b and inhibits downstream activation [41]. In the terminal stage of complement activation, protectin (CD59) inserts into the membrane at sites of C5b–8 complex formation to block C9 polymerization, preventing completion of the membrane attack complex (MAC) and protecting host cells from lysis [39, 40]. These CRPs are widely expressed across human tissues, particularly in highly vascularized organs, such as the liver, spleen, kidneys, lungs, and heart, which are continuously exposed to circulating complement components via the bloodstream. Dysregulation or genetic mutations affecting CRPs can result in pathological complement activation, contributing to autoimmune or inflammatory disorders [38, 41]. Complement regulation thus represents an attractive therapeutic target in complement-driven diseases. Recent research further highlights novel roles, including interactions between complement and the gut microbiota in IBD. Dysbiosis, which is characterized by reduced microbial diversity and an over-representation of pro-inflammatory taxa, has been shown to enhance alternative pathway activation through microbial surface patterns that directly trigger complement components. This sustained activation not only exacerbates epithelial injury but also perpetuates mucosal inflammation, creating a vicious cycle between microbial imbalance and immune dysregulation [15]. Complement activation in IBD: clinical and experimental evidence Accumulating clinical and experimental data highlight the central role of the complement system in the pathogenesis of IBD, particularly UC. Complement activation has been consistently observed in both systemic circulation and inflamed intestinal tissues of UC patients, implicating mucosal immune dysregulation and chronic inflammation [42–44]. Clinical evidence in UC Complement effector products and UC pathogenesis Multiple clinical studies have demonstrated hyperactivation of the complement system in both the colonic mucosa and systemic circulation of UC patients. Elevated levels of complement activation products, including C3a, C5a, and MAC, have been detected in serum, feces, and colonic biopsies, particularly during active disease phases [17–22]. Immunohistochemical analyses have demonstrated deposition of C3, MAC, and other complement fragments in inflamed intestinal tissues, especially along the damaged epithelium, vascular endothelium, and within the lamina propria [17]. These findings suggest that all three activation pathways contribute to sustained local activation of complement within the colonic mucosa. These activation products play pivotal roles in UC pathogenesis. C3a and C5a are potent anaphylatoxins, inducing vascular permeability, mast cell degranulation, and neutrophil chemotaxis. The immune cell infiltration triggers the release of proinflammatory cytokines, such as TNF-α and IL-6, contributing to mucosal inflammation [43]. These changes further disrupt tight junctions between epithelial cells, exacerbating barrier dysfunction and perpetuating complement activation in a feedforward loop. Importantly, elevated serum C5a levels have been positively correlated with clinical disease activity scores, endoscopic severity, and histological indices of inflammation. Longitudinal studies, including a 2020 cohort confirmed by 2024 reviews, show that elevated C5/C5a levels can predict the development of IBD, including UC, up to 5 years prior to clinical onset, highlighting their potential as prognostic biomarkers [32, 45–47]. Similarly, MAC deposition on intestinal epithelial cells is associated with increased apoptosis, loss of barrier integrity, and activation of proinflammatory transcription factors, such as NF-κB, further exacerbating mucosal injury [48]. Collectively, these findings demonstrate that complement effector products, particularly C3a, C5a, and MAC, play a critical role in UC pathogenesis. Their elevated levels correlate with disease activity and prognosis, identifying them as both potential biomarkers and therapeutic targets. Regulatory failure and protective components In contrast to the pathogenic roles of complement effector molecules, several initiator and regulatory components of the complement system contribute to mucosal protection and immune homeostasis in UC. C1q and MBL, key initiators of the classical and lectin pathways, respectively, facilitate the clearance of apoptotic cells and suppress chronic inflammation. Reduced mucosal expression of C1q in UC patients has been associated with impaired apoptotic cell clearance, leading to the accumulation of danger signals and persistent mucosal inflammation [23]. In addition, CRPs such as CD55 (decay-accelerating factor, DAF) and CD59 (protectin) are often downregulated in inflamed colonic tissues of UC patients, especially during active phases of the disease [49–51]. This regulatory deficiency permits uncontrolled complement activation, resulting in bystander epithelial damage and apoptosis. The observed downregulation may result from transcriptional suppression by pro-inflammatory cytokines, such as TNF-α or IFN-γ, or from enzymatic shedding of CRPs from the epithelial cell surface, both of which are common in inflamed mucosal environments. Recent single-cell RNA sequencing (scRNA-seq) analyses have further revealed dysregulated expression of CD46, CD55, CD59, and C6 within Th17 cells in UC-affected tissues. These findings underscore the essential role of CRPs in maintaining epithelial barrier integrity, modulating mucosal immunity, and preserving immune tolerance [32, 47, 52]. Collectively, this evidence supports a model in which dysregulated complement activity, marked by excessive effector activation and inadequate regulatory control, drives UC pathogenesis. This imbalance perpetuates chronic inflammation, disrupts epithelial repair, and compromises mucosal barrier function. Insights from DSS-induced colitis models The DSS-induced mouse colitis model is widely used to investigate the pathophysiological mechanisms. DSS primarily causes chemical injury to the intestinal epithelium. Upon oral administration, mice develop acute colitis characterized by mucosal ulceration, innate immune activation, and robust activation of the complement cascade [33, 53, 54]. While this model is valuable for controlled temporal analysis of immune responses, including complement activation, it has important limitations. Notably, DSS-induced colitis does not fully replicate the chronic, relapsing–remitting nature of human UC, nor does it adequately capture the complex interplay among host genetics, adaptive immunity, and microbiota. Therefore, findings from DSS models must be interpreted cautiously and ideally complemented by other models and clinical data to achieve translational relevance. DSS induces strong local complement activation within the colonic mucosa. Both early complement components (e.g., C1q, MBL, and C3) and terminal effectors (e.g., C5a and MAC) contribute to disease progression in distinct and sometimes opposing roles, depending on the inflammatory phase and cellular context [23–25]. Early complement components: dual roles in inflammation and repair Among the early complement components, C3 serves as the central hub for all three activation pathways and plays a predominantly pathogenic role in colitis. In acute colitis models, C3-deficient mice exhibit significantly reduced disease severity, including diminished epithelial injury, lower histological inflammation scores, reduced cytokine levels, and improved clinical indices such as reduced weight loss and preserved colon length compared to wild-type controls [55]. These findings suggest that C3 activation exacerbates mucosal inflammation, likely through the generation of C3a, which recruits neutrophils and monocytes, and C3b, a potent opsonin that promotes immune cell activation and inflammation when dysregulated [28]. Building on this, Schepp-Berglind et al. demonstrated that pharmacological inhibition of complement activation similarly attenuates the disease. Mice treated with CR2–fH, a targeted inhibitor of the alternative pathway, and CR2–Crry, a broader inhibitor acting at the level of the C3 convertase, showed reduced histological damage and cytokine expression [23, 56]. These results underscore the central role of the alternative pathway in mediating complement-driven inflammation in colitis. Further reinforcing the pathogenic role of complement activation, Wende et al. evaluated genetic deletion of the C3a receptor (C3aR) in BALB/c mice in DSS-induced colitis model. C3aR-deficient mice showed significant disease attenuation, including reductions in weight loss, histological scores, CXCL1 mRNA, and IL-6 levels [57]. Interestingly, Zhang et al. demonstrated that C3a/C3aR signaling exerts stage-dependent, dual effects in experimental colitis. Inhibition of C3aR during early disease stages unexpectedly worsened colonic injury and increased inflammatory cytokine levels, an effect attributed to the upregulation of caspase-11-mediated pyroptosis. In contrast, late-stage C3aR inhibition attenuated inflammation and promoted mucosal recovery. These findings indicate that C3a/C3aR signaling plays a context-dependent role, aggravating inflammation when blocked prematurely via caspase-11 activation, but facilitating resolution when modulated during disease recovery [58]. Recent evidence from C3 knockout mice in chronic DSS models further supports this conclusion, showing that the absence of C3 can paradoxically exacerbate inflammation in the colon during prolonged disease, emphasizing dose- and time-dependent mechanisms [59]. Despite these findings, complement activation is not uniformly harmful, and certain complement components exert protective roles in colitis. C1q, the recognition molecule of the classical pathway, has been shown to possess mucosal healing and anti-inflammatory functions in acute DSS-induced colitis. While early complement activation may contribute to inflammation, recent studies have highlighted a protective role for C1q. Supporting this, C1q/MBL double-deficient mice exhibited more severe colitis, characterized by exacerbated mucosal damage and impaired recovery, compared to wild-type controls, suggesting that the classical and lectin pathways contribute to host defense and tissue repair [23]. These findings implicate the classical and lectin pathways in apoptotic cell clearance, control of bacterial overgrowth, and promotion of epithelial regeneration, thereby supporting mucosal homeostasis. In contrast, the alternative pathway appears to play a detrimental role during acute inflammation, reinforcing the concept that the complement system exerts dual and context-dependent effects in colitis. Further supporting the protective function of the classical pathway, Gunji et al. investigated the role of C1q in intestinal epithelial repair following acute DSS-induced injury [25]. C1q expression was markedly upregulated in intestinal epithelial cells (IECs) during the recovery phase, particularly in regions undergoing active regeneration. This upregulation correlated with increased expression of proliferation and repair markers, such as Ki67 and Lgr5, indicating that C1q may directly promote epithelial healing [25]. Collectively, these findings suggest that C1q promotes mucosal repair and regeneration, potentially by enhancing apoptotic cell clearance and supporting intestinal stem cell proliferation. The dual role of C1q underscores the phase-specific and spatially dependent nature of early complement components, which may exert pro-inflammatory or pro-repair functions depending on the timing and localization of activation. Terminal complement effectors: C5a and MAC in mucosal injury The terminal complement effectors, including C5a, its receptor C5aR1 (CD88), and the MAC, are key mediators of epithelial injury and inflammatory amplification in UC. Activation of the complement cascade leads to cleavage of C5 into C5a, a potent anaphylatoxin, and C5b, which initiates MAC formation. These terminal components play a pivotal role in orchestrating immune cell recruitment, epithelial damage, and local inflammatory responses at sites of active colonic inflammation [24, 43, 60]. C5a is one of the most potent anaphylatoxins. Binding to C5aR1 on neutrophils, monocytes, macrophages, or endothelial cells, C5a triggers a cascade of inflammatory processes, including chemotaxis, cytokine production, oxidative burst, and degranulation [28, 37]. Supporting its pathogenic role, Woodruff et al. demonstrated that a C5aR antagonist markedly reduced the severity of colitis induced by trinitrobenzenesulfonic acid (TNBS), leading to decreased colon edema, reduced TNF-α levels, and improved survival and nutritional status of the rat subjects [61]. Similarly, Chen et al. reported that anti-C5a neutralizing antibodies attenuated intestinal damage, suppressed neutrophil infiltration, and lowered cytokine production in the same model [43]. In DSS-induced colitis models, pharmacological blockade of C5aR signaling significantly reduced leukocyte infiltration, mucosal injury, and proinflammatory cytokine expression (e.g., IL-4 and IL-10) [62, 63]. Moreover, neutralizing C5 antibodies effectively ameliorated DSS-induced colitis. Treated animals exhibited complete prevention of weight loss, significant reductions in disease activity index, colonic weight/length ratio, histological damage, myeloperoxidase activity, and inflammatory cytokine expression (TNF-α, IL-1β, and IL-6) [62]. Taken together, these findings highlight the central role of the C5a–C5aR1 axis in driving acute colonic inflammation. In parallel, the MAC, assembled from C5b, C6, C7, C8, and multiple units of C9, exerts cytotoxic effects by forming pores in cell membranes, leading to osmotic lysis or sublytic signaling [60]. Although MAC formation serves as a critical defense against extracellular pathogens, excessive or dysregulated MAC deposition on intestinal epithelial cells can cause host cell apoptosis, tissue necrosis, and barrier disruption, hallmarks of UC pathology. Histological analyses of colonic biopsies from UC patients have revealed increased MAC deposition, particularly in crypt abscesses and ulcerated regions. Importantly, regulators of MAC formation, such as CD59 (protectin), are frequently downregulated or functionally impaired in IBD, compromising epithelial resistance to complement-mediated lysis [49, 51]. A 2024 single-cell RNA-seq study in UC patients and models highlights altered expression of CD59 and CD55 in Th17 cells, potentially linking to dysregulated T cell responses and sustained inflammation [52]. Dysregulation of these complement inhibitors may permit uncontrolled activation of the complement system, creating a self-perpetuating inflammatory loop that exacerbates mucosal injury. Taken together, these findings illustrate the dual roles of terminal complement components. While C5a–C5aR1 signaling and MAC deposition contribute to epithelial injury and inflammatory amplification, they may also play roles in pathogen clearance and tissue repair. These insights underscore the importance of pathway-specific and phase-dependent complement modulation as a therapeutic strategy aiming to attenuate pathogenic activation without abolishing the protective functions of the complement system. The bidirectional role underscores the need for targeted, context-specific therapies to harness protective aspects while mitigating harm. Table 1 summarizes the dual roles of key complement components based on studies of clinical UC and DSS-induced colitis.Table 1.Complement components’ dual roles in UC Table 1.Complement components’ dual roles in UC Complement components’ dual roles in UC Therapeutic potential of complement-targeted interventions The complement system, as a central modulator of innate immunity and inflammation, presents a promising therapeutic target for UC. Given the dual roles observed in both clinical settings and DSS-induced models, selective inhibition of pro-inflammatory effectors, particularly C5a, C5aR1, and MAC formation, has attracted considerable attention in translational research [5, 7, 64]. Preclinical agents and efficacy Several C5a-targeting agents have shown efficacy in experimental colitis models. PMX53, a cyclic peptide antagonist of C5aR1, has been demonstrated to reduce neutrophil infiltration, cytokine production, and epithelial damage in DSS-treated mice [65]. PMX205, a derivative of PMX53, was specifically developed to improve oral bioavailability and enhance local action in the colon. This colon-targeted formulation demonstrated superior efficacy, likely due to optimized mucosal delivery and reduced systemic exposure, thereby minimizing off-target effects [63, 66]. C3-targeting inhibitors have also emerged as potential therapies. For example, APL-9, a PEGylated derivative of the C3 inhibitor compstatin, displayed broad inhibition of complement activation with reduced systemic effects [67, 68]. Clinical and investigational therapies Beyond preclinical studies, eculizumab, a monoclonal antibody that blocks C5 cleavage, is already approved for complement-mediated diseases, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). However, its use in inflammatory bowel disease (IBD) remains investigational, largely due to concerns about systemic complement inhibition compromising host defenses [69]. While large-scale phase III clinical trials for UC remains to be conducted, exploratory studies continue to evaluate its potential in complement-driven IBD and IBD-driven disease [70–72]. The absence of clinical advancement in IBD may reflect both scientific and commercial hurdles: namely, the stringent efficacy and safety benchmarks already set by established biologics, and the potential risk-to-benefit imbalance of using potent systemic immunomodulators in a non-fatal, chronic disease. More targeted agents like avacopan (CCX168), an oral C5aR1 antagonist approved for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, have similarly not progressed to dedicated IBD trials. Nonetheless, its success in other inflammatory diseases positions it as a potential future candidate for UC, offering more localized immune modulation. Still, its limited development in IBD trials may reflect caution over infection risks and the challenge of surpassing the efficacy and safety profile of existing therapies [73]. Emerging complement-targeted strategies and future directions in UC therapy Emerging strategies include locally acting complement inhibitors, dual-acting biologics, and gene therapy to restore complement regulation. For example, local delivery of CD55 or CD59-expressing vectors has been proposed to limit mucosal complement activation without affecting systemic immunity [40]. In addition, nanoparticle-based drug delivery systems are under investigation to enhance mucosal specificity and reduce systemic exposure. A recent study demonstrated the efficacy of pH-sensitive nanoparticles for colon-targeted inhibition of C5aR1, significantly ameliorating experimental colitis by reducing local inflammation with minimal systemic effects [66]. This approach builds on broader advancements in nanoparticle systems for IBD, including lipid-based and polymeric nanoparticles that revolutionize targeted delivery [74]. However, complement modulation in UC must account for the protective functions of upstream components, such as C1q and MBL, which aid in epithelial repair, apoptotic cell clearance, and microbial control [25]. Thus, timing, disease stage, and target specificity are critical considerations for therapeutic success. Future research should focus on developing biomarker-guided therapeutic approaches, such as using fecal or serum levels of complement activation products (e.g., C3a and C5a) to assess disease activity and tailor individualized treatment strategies. Recent initiatives, like the FNIH Biomarkers Consortium project, aim to transform UC clinical trials by identifying biomarkers for mucosal healing, potentially integrating complement activation markers for precision therapy [75]. Stage-specific interventions are essential for selective inhibition of pro-inflammatory effectors during active flares, so upstream complement functions involved in tissue repair and immune regulation may be preserved. Finally, combination therapies that integrate complement-targeted agents with existing biologics, such as anti-TNF or anti-IL-23 monoclonal antibodies, may provide synergistic effects and offer broader immunomodulatory benefits. Emerging evidence supports dual therapy in IBD by targeting complementary immune pathways for improved efficacy and safety [76]. This aligns with updated ACG guidelines emphasizing advanced targeted therapies for UC management [77]. As summarized in Table 2, these therapies highlight key mechanisms, outcomes, and challenges, providing a roadmap for future clinical translation.Table 2.Complement-targeted therapies in IBD. Table 2.Complement-targeted therapies in IBD. Complement-targeted therapies in IBD. Conclusion and future outlook Clinical and experimental evidence consistently demonstrate that dysregulated complement activation contributes to UC pathogenesis. Epithelial damage, barrier dysfunction, and mucosal inflammation, particularly through effector molecules, such as C3a, C5a, and the MAC. At the same time, initiator components C1q and MBL, as well as complement regulators CD55 and CD59, exert protective or restorative functions, highlighting the dualistic nature of the complement system. Insights from DSS-induced colitis models confirm that the impact of complement varies by disease phase, underscoring the therapeutic potential of complement-targeted interventions. Several agents, including C5aR1 antagonists, C3 inhibitors, and MAC blockers, have shown efficacy in preclinical studies. However, careful patient stratification based on complement biomarkers, stage-specific therapeutic timing, and preservation of homeostatic complement functions remain crucial for ensuring efficacy and safety. Looking ahead, future research should prioritize the identification of reliable biomarkers, such as serum or fecal levels of C3a, C5a, and other activation products, to monitor complement dynamics in UC, to enable better patient stratification and therapeutic guidance. Biomarker-stratified clinical trials and interventions tailored to specific disease stages will be critical for translating experimental therapies into clinical success. Mucosa-specific inhibitors and nanoparticle delivery systems have the potential of targeting pathological inflammation while sparing systemic immunity. Combining complement-targeted therapies with genomic, microbiome, and metabolite profiling in personalized medicine frameworks holds promise for enhancing treatment precision, long-term remission, and quality of life in IBD patients. A deeper understanding of the complement system’s regulatory balance in UC will not only enrich our knowledge of disease mechanisms but also pave the way for innovative, precision-based strategies that could transform IBD care in the coming years.